Entity

Time filter

Source Type

Cali, Colombia

Guyette F.,University of Pittsburgh | Suffoletto B.,University of Pittsburgh | Castillo J.-L.,Fundacion Valle del Lili | Quintero J.,University of Pittsburgh | And 2 more authors.
Journal of Trauma - Injury, Infection and Critical Care | Year: 2011

Background: Lactate is associated with morbidity and mortality; however, the value of prehospital lactate (pLA) is unknown. Our objective was to determine whether pLA improves identification of mortality and morbidity independent of vital signs. Methods: We measured pLA in 1,168 patients transported by rotorcraft to a Level I trauma center over 18 months. The primary outcome was in-hospital mortality; secondary outcomes were emergent surgery and multiple organ dysfunction syndrome (MODS). Covariates include age, sex, prehospital vital signs, and mental status. We created multivariable logistic regression models and tested them for interaction terms and goodness of fit. Cutoff values were established for reporting operating characteristics using shock (defined as shock index >0.8, heart rate >110, and systolic blood pressure <100), tachypnea (RR ≥30), and altered sensorium (Glasgow Coma Scale score <15). Results: In-hospital mortality was 5.6%, 7.4% required surgery and 5.7% developed MODS. Median lactate was 2.4 mmol/L. Lactate was associated with mortality (odds ratio [OR], 1.23; p < 0.0001), surgery (OR, 1.13; p < 0.001), and MODS (OR, 1.14; p < 0.0001). Inclusion of pLA into a logistic model significantly improved the area under the receiver operator curves from 0.85 to 0.89 for death (p < 0.001), 0.68 to 0.71 for surgery (p = 0.02), and 0.78 to 0.81 for MODS (p = 0.002). When a threshold lactate value of >2 mmol/L was added to a predictive model of shock, respiratory distress, or altered sensorium, it improved sensitivity from 88% to 97% for death, 64% to 86% for surgery, and 94% to 99% for MODS. Conclusion: The pLA measurements improve prediction of mortality, surgery, and MODS. Lactate may improve the identification of patients who require monitoring, resources, and resuscitation. Copyright © 2011 by Lippincott Williams & Wilkins. Source


Bonilla-Abadia F.,ICESI University | Echeverri A.F.,CES University | Carbonell J.P.,Fundacion Valle del Lili | Canas C.A.,ICESI University
Rheumatology International | Year: 2014

We report an adult female patient with Takayasu arteritis (TA) receiving conventional medical treatment and anti-TNF therapy, which developed progressive thoracic and abdominal aortic aneurysms. She developed imminent rupture of the thoracic aneurysm and an endovascular stent-graft (EVSG) was emergency implanted and a year after this procedure the abdominal aneurysm increased in size requiring reoperation and placement of another EVSG. Both procedures had a very good outcome. This case shows the effectivity and security of multiple EVSG implantations in multiple aortic aneurisms in patients with TA. © 2013 Springer-Verlag. Source


Betancur J.F.,Fundacion Valle del Lili | Betancur J.F.,CES University | Bonilla-Abadia F.,ICESI University | Hormaza A.A.,ICESI University | And 3 more authors.
Lupus | Year: 2016

Aim The aim of this study was to describe a case series of patients with primary or secondary antiphospholipid syndrome (APS) treated with direct oral anticoagulants (DOACs). Patients and methods Clinical charts of eight patients with thrombotic primary or secondary APS treated with direct oral anticoagulants (DOACs) between January 2012 and May 2015 were reviewed. Results The mean age was 45 ± 14.36 (range 27-69 years). Four patients had secondary APS (50%). All patients were initially treated with warfarin by a mean time of 70.87 ± 57.32 months (range 17-153 months). Changes in anticoagulation were defined by recurring thrombosis in five patients (62.5%) and life-threatening bleeding in the other three cases. Seven patients (87.5%) received rivaroxaban treatment and one patient (12.5%) apixaban. The mean follow-up period with DOACs was 19 ± 10.06 months (range 2-36 months). There was no recurrence of thrombosis by the time of data collection. Conclusions Despite not being the standard treatment in APS, we propose DOACs as a rational alternative for the management of patients with this diagnosis. Further interventional clinical studies are necessary for possible standardization of this therapy in APS patients. © SAGE Publications. Source


Majid A.,Beth Israel Deaconess Medical Center | Fernandez L.,Fundacion Valle del Lili | Fernandez-Bussy S.,University of Florida | Herth F.,Thoraxklinik | Ernst A.,Beth Israel Deaconess Medical Center
Archivos de Bronconeumologia | Year: 2010

Tracheobronchomalacia is a central airway disease characterised by weakness of the wall and dynamic decrease in the tracheal lumen and the large bronchi, particularly while exhaling. It is more common in middle age and the elderly with previous exposure to cigarettes. It causes chronic symptoms such as cough, dyspnea, increase in recurrent infections, and poor secretion management, but it can also progress to chronic respiratory failure and death. It is usually confused with other common diseases like chronic obstructive pulmonary disease (COPD) or asthma. Its causes can be congenital or acquired and its diagnosis involves the dynamic assessment of the airway with tomography and fibrobronchoscopy. It is classified as mild, moderate or severe depending on the degree of collapse of the airway when exhaling. Management consists of a primary phase, in which concomitant diseases must be controlled, such as COPD, asthma or gastro-oesophageal reflux. In diffuse moderate to severe symptomatic tracheobronchomalacia tracheobronchoplasty must be considered with strengthening of the posterior wall. Silicone and "Y" stents can be used to identify patients who could potentially benefit from surgical treatment as well as being used for the definitive symptomatic treatment with high surgical risk. More prospective studies need to be done in order to standardise certain common criteria for the management of this usually under-diagnosed disease. © 2009 SEPAR. Source


Maiti A.K.,Oklahoma Medical Research Foundation | Kim-Howard X.,Oklahoma Medical Research Foundation | Viswanathan P.,Oklahoma Medical Research Foundation | Guillen L.,University of Buenos Aires | And 10 more authors.
Arthritis and Rheumatism | Year: 2010

Objective. Autoimmune diseases often have susceptibility genes in common, indicating similar molecular mechanisms. Increasing evidence suggests that rs6822844 at the IL2-IL21 region is strongly associated with multiple autoimmune diseases in individuals of European descent. This study was undertaken to attempt to replicate the association between rs6822844 and 6 different immune-mediated diseases in non-European populations, and to perform disease-specific and overall meta-analyses using data from previously published studies. Methods. We evaluated case-control associations between rs6822844 and celiac disease (CD) in subjects from Argentina; rheumatoid arthritis (RA), type 1 diabetes mellitus (DM), primary Sjögren's syndrome (SS), and systemic lupus erythematosus (SLE) in subjects from Colombia; and Behçet's disease (BD) in subjects from Turkey. Allele and gene distributions were compared between cases and controls. Meta-analyses were performed using data from the present study and previous studies. Results. We detected significant associations of rs6822844 with SLE (P = 0.008), type 1 DM(P = 0.014), RA (P = 0.019), and primary SS (P = 0.033) but not with BD (P = 0.34) or CD (P = 0.98). We identified little evidence of population differentiation (FST = 0.01) within cases and controls from Argentina and Colombia, suggesting that association was not influenced by population substructure. Disease-specific meta-analysis indicated significant association for RA (Pmeta = 3.61 × 10-6), inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis) (Pmeta = 3.48 × 10-12), type 1 DM (Pmeta = 5.33 × 10-5), and CD (Pmeta = 5.30 × 10-3). Overall meta-analysis across all autoimmune diseases reinforced association with rs6822844 (23 data sets; Pmeta = 2.61 × 10-25, odds ratio 0.73 [95% confidence interval 0.69-0.78]). Conclusion. Our results indicate that there is an association between rs6822844 and multiple autoimmune diseases in non-European populations. Metaanalysis results strongly reinforce this robust association across multiple autoimmune diseases in both European-derived and non-European populations. © 2010, American College of Rheumatology. Source

Discover hidden collaborations